180518-75-6

Basic information

• Product Name: 1H-Pyrazole-3-carboxylicacid,5-methoxy-,ethylester(9CI)
• Synonyms: 1H-Pyrazole-3-carboxylicacid,5-methoxy-,ethylester(9CI);5-Methoxy-1H-pyrazole-3-carboxylic acid ethyl ester
• CAS NO: 180518-75-6
• Molecular Formula: C7H10N2O3
• Molecular Weight: 170.17
• Product Categories: GLYCINESCAFFOLD
• Mol File: 180518-75-6.mol

Chemical Properties

• Boiling Point: 328.1±22.0 °C(Predicted)
• Appearance: /
• Density: 1.220±0.06 g/cm3(Predicted)
• PKA: 10.08±0.10(Predicted)
• CAS DataBase Reference: 1H-Pyrazole-3-carboxylicacid,5-methoxy-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylicacid,5-methoxy-,ethylester(9CI)(180518-75-6)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylicacid,5-methoxy-,ethylester(9CI)(180518-75-6)

Safety Data

• Hazardous Substances Data: 180518-75-6(Hazardous Substances Data)

Upstream product

• 85230-37-1 ethyl 5-hydroxy-1H-pyrazole-3-carboxylate 
• 74-88-4 methyl iodide 

Downstream Products

• 881693-06-7 5-Methoxy-1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidin-2-one compounds (also referred to herein as "FRPPO compounds"), that, inter alia, inhibit glutaminyl-peptide cyclotransferase-like (isoQC) enzyme and/or glutaminyl-peptide cyclotransferase (QC) enzyme (e.g., inhibit or reduce or block the activity or function of isoQC and/or QC enzyme). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit isoQC and/or QC enzyme; to treat disorders that are ameliorated by the inhibition of isoQC and/or QC enzyme; to treat cancer, atherosclerosis, fibrotic diseases, infectious diseases, Alzheimer's disease, etc.

HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS

The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.

Tricycles, their manufacture and use as pharmaceutical agents

The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.